The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel discussed:
- When is the right time to get acquired?
- What is the survival rate of c-suite after an acquisition?
- Why is an acquisition better than a collaboration?
- What are the key issues in the due diligence process that can hurt the value of the deal?
- How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
- What types of steps can be taken to prepare a forecast that drives value negotiations
- How can this analysis be leverage in negotiating a collaborative or co-partner agreement
Presenters included:
- Todd Boudreau, Senior Counsel, Private Equity & Venture Capital Practice, Foley
- Dr. Ton Bunt, Senior Advisor, JSB Partners LP
- Sven Riethmueller, Of Counsel, Private Equity & Venture Capital, Foley
- David Schechner, Managing Director, Canaccord Adams
- Shane Senior, Managing Director, Crosstree Capital Partners Inc.
Related Insights
April 3, 2026
Energy Current
Texas Legislature Sets Its Sights on Data Centers and AI: What You Need to Know
Texas House and Senate leadership recently released their interim charges, which serve as "homework assignments" for legislative…
April 3, 2026
Foley Viewpoints
For Your Eyes Only? Not Quite: Shadow AI in the Workplace
While many companies are still developing governance frameworks for authorized AI tools, an emerging risk has quietly surfaced: employees using unauthorized transcription tools without the company’s or participants’ consent.
April 3, 2026
Manufacturing Industry Advisor
Connecticut Appellate Court Narrows Scope of Petroleum “Franchise” Protections for Gas Station Operators
The Appellate Court of Connecticut affirmed a trial court’s judgment in favor of a petroleum distributor/lessor, holding that convenience…